Term
Biosimilars
Biologic medicines similar to approved originals, regulated by the Health Ministry to ensure their quality and safety in the Lebanese market.
Biosimilars are biologic medicines similar to approved reference products, developed after patents expire. They differ from ordinary generics because they are produced from living organisms, requiring special approval standards. Lebanon's Health Ministry announced it would re-review their files according to updated WHO standards.
Written by AI and not yet reviewed by an editor.